Treatment of pigs with PCV2 antigen
The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. Preferably, those animals are pigs or young piglets.
1. A method for the treatment of
a) PCV2 infection; or
b) clinical symptoms caused by or associated with a PCV2 infection in piglets, wherein the piglet has anti-PCV2 antibodies, the method comprising the step of administering a single efficacious dose of an immunogenic composition comprising a PCV2 ORF2 antigen to a piglet.
2. The method according to claim 1 , wherein said anti-PCV2 antibodies are maternal antibodies.
3. The method according to claim 1 , wherein the immunogenic composition comprising PCV2 ORF2 antigen is administered at day 7 of age or later.
4. The method according to claim 1 , wherein the immunogenic composition comprising PCV2 ORF2 antigen is administered at day 14 of age or later.
5. The method according to claim 1 , wherein the immunogenic composition comprising PCV2 ORF2 antigen is administered not later than at week 7 of age.
6. The method according to claim 1 , wherein the treatment results in shortening of the viremia phase of 5 or more days as compared to piglets of a non-treated control group.
7. The method according to claim 1 , wherein said PCV2 ORF2 antigen is expressed by a recombinant baculovirus prior to administration.
8. The method according to claim 1 , wherein said PCV2 ORF2 antigen is included in Ingelvac® CircoFLEX™.
9. The method according to claim 1 , wherein said treatment of PCV2 infection results in an improvement in comparison to piglets of a non-treated control group in a vaccine efficacy parameter selected from the group consisting of a reduction in the loss of weight gain, a shorter duration of viremia, a lower virus load, or any combination thereof.
10. The method of claim 1 , wherein the piglet has anti-PCV2 antibodies with an anti-PCV2 antibody titer of at least 1:100-1:320 as determined in a PCV-specific indirect immunofluorescence assay.
11. The method according to claim 10 , wherein the piglet has said anti-PCV2 antibody titre at the time the immunogenic composition comprising PCV2 ORF2 antigen is administered.
12. The method of claim 1 , wherein the piglet has anti-PCV2 antibodies with an anti-PCV2 antibody titer of up to 1:1000 as determined in a PCV-specific indirect immunofluorescence assay.
13. The method of claim 1 , wherein the piglet has anti-PCV2 antibodies with an anti-PCV2 antibody titer of greater than 1:1000 as determined in a PCV-specific indirect immunofluorescence assay.
14. A method for the treatment of a PCV2 infection or for the reduction of the severity of clinical symptoms caused by PCV2 infection in piglets, wherein the piglets have anti-PCV2 antibodies with an anti-PCV2 antibody titer of more than 1:1000 as determined in a PCV-specific indirect immunofluorescence assay, comprising administering a single efficacious dose of a vaccine composition comprising a PCV2 ORF2 antigen to a piglet wherein the treatment of PCV2 infection or the reduction of the severity of clinical symptoms caused by or associated with a PCV2 infection occurs after the single efficacious dose of the vaccine composition comprising PCV2 ORF2 antigen.
15. The method of claim 14 , wherein the PCV2 ORF2 antigen is a PCV2 ORF2 protein.
16. The method of claim 14 , wherein the anti-PCV2 antibodies are maternally-derived antibodies.
17. The method of claim 14 , wherein the vaccine composition comprising PCV2 ORF2 antigen is administered at day 7 of age or later.
18. A method for the treatment of PCV2 infection in a piglet or for the reduction of the severity of clinical symptoms caused by or associated with a PCV2 infection in a piglet, wherein the piglet has anti-PCV2 antibodies, the method comprising the step of:
administering a single efficacious dose of an immunogenic composition comprising PCV2 ORF2 protein to a piglet, wherein the PCV2 ORF2 protein has at least 90% sequence homology with SEQ ID NO. 11 and wherein the treatment of PCV2 infection or the reduction of the severity of clinical symptoms caused by or associated with a PCV2 infection occurs after the single efficacious dose of said immunogenic composition comprising PCV2 ORF2 protein.
19. The method of claim 18 , wherein the piglet has anti-PCV2 antibodies with an anti-PCV2 antibody titer of at least 1:1001:320 as determined in a PCV-specific indirect immunofluorescence assay.